Clinical trials: Geographic Atrophy
Dry Age-related Macular Degeneration
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm
- Trial name
- NCT07770828
- Testing
- OCU410
- Where
- 3 sites in United States
- Volunteers
- 237 people
- Sponsor
- Ocugen
Age-Related Macular Degeneration, Geographic Atrophy
Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD
To evaluate the effectiveness of subthreshold laser treatment on retinal sensitivity in patients with reticular pseudodrusen and incipient Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Reticular Pseudodrusen
- Trial name
- NCT02800356
- Testing
- Subthreshold 577 nm yellow wavelength laser photo-coagulator
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Ospedale San Raffaele
Age-Related Macular Degeneration
Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)
To evaluate the safety and efficacy of eculizumab for the treatment of dry AMD as evaluated by the change in drusen volume and area of geographic atrophy.
- Trial name
- COMPLETE (NCT00935883)
- Testing
- Eculizumab, Saline
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Philip J. Rosenfeld, MD, PhD
Geographic Atrophy
Safety and Efficacy Study of Novel Gene Therapy AGX-08 for Geographic Atrophy
This is AGX-08's safety, tolerability, and efficacy in Geographic Atrophy first-in-human study. This trial is meant to evaluate the safety and efficacy of AGX-08 in Geographic Atrophy patients.
- Trial name
- NCT07602127
- Testing
- AGX-08-L, AGX-08-H, AGX-08-S
- Volunteers
- 24 people
- Sponsor
- Zhongmou Therapeutics
Age-related Macular Degeneration
Fundus Autofluorescence Imaging in Age-related Macular Degeneration Using Confocal Scanning Laser Ophthalmoscopy
The purpose of this study is to define phenotypic variations in atrophic Age-Related Macular Degeneration (AMD) and to identify predictive factors for disease progression based on fundus autofluorescence imaging.
- Trial name
- NCT00393692
- Where
- 7 sites in Germany
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Age-Related Macular Degeneration
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of…
- Trial name
- NCT03178149
- Testing
- ASP7317, tacrolimus, trimethoprim-sulfamethoxazole
- Where
- 20 sites in United States
- Volunteers
- 42 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Geographic Atrophy, Age-related Macular Degeneration
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
This study was conducted in two parts; Part A and Part B: Part B was initially planned to include two cohorts. Cohort 2 was cancelled following an interim analysis for efficacy in Part A of the study, and not due to any safety…
- Trial name
- NCT01527500
- Testing
- LFG316, LFG316 Lower dose
- Where
- 19 sites in United States
- Volunteers
- 158 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration, Geographic Atrophy
Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study
This study is being conducted to assess two imaging methods-central microperimetry and radial OCT (Optical Coherence Tomography)-in patients with Geographic Atrophy (GA) or those who are at risk of developing this condition.
- Trial name
- CORE-GA (NCT07556406)
- Testing
- Optical coherence tomography, Microperimetry
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of California, San Francisco
Age-Related Macular Degeneration, Geographic Atrophy
Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
This study is being done to determine the long-term safety and possible benefits of transplanted Human Central Nervous System Stem Cells (HuCNS-SC) for patients with Geographic Atrophy of Age-Related Macular Degeneration.
- Trial name
- NCT02137915
- Testing
- Human Central Nervous System Stem Cells
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- StemCells, Inc.
Geographic Atrophy, Macular Degeneration
A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration
This study will assess the safety and efficacy of the brimonidine intravitreal implant in participants with geographic atrophy due to age-related macular degeneration.
- Trial name
- BEACON (NCT02087085)
- Testing
- 400 µg Brimonidine Implant
- Where
- 41 sites in United States, Australia and 4 more
- Volunteers
- 310 people
- Sponsor
- Allergan
Age-Related Macular Degeneration, Geographic Atrophy
Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO
To conduct a precision study to assess the microperimetry function of the Spectral OCT/SLO. The study will assess variability across measurements taken by three different operator-device configuration across clinical sites…
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema
- Trial name
- NCT01692938
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Optos, PLC
Age-related Macular Degeneration, Age-related Maculopathy
GARM II: A Study on the Genetics of Age-related Maculopathy
The original study (GARM I) has been conducted for more than 18 years at the University of Pittsburgh Medical Center (UPMC). GARM II is a nationwide research study about age-related macular degeneration in the next generation of…
- Trial name
- NCT01115387
- Testing
- Observational-1, Observational-2
- Where
- 2 sites in United States
- Volunteers
- 603 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD).
- Trial name
- SIENNA (NCT06541704)
- Testing
- Pozelimab, Cemdisiran
- Where
- 231 sites in United States, Australia and 9 more
- Volunteers
- 975 people
- Sponsor
- Regeneron Pharmaceuticals
Dry Age-related Macular Degeneration
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration
In this study, the principle functionality of the device will be tested in humans for the first time. The study will evaluate the extent to which patients with atrophic dry age related macular degeneration (AMD) have evoked light…
- Trial name
- PRIMA FS (NCT03333954)
- Testing
- PRIMA Bionic Vision System
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Science Corporation
Geographic Atrophy
Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with Geographic Atrophy associated with Age-Related…
- Trial name
- FILLY (NCT02503332)
- Testing
- Pegcetacoplan
- Where
- 46 sites in United States, Australia and 1 more
- Volunteers
- 246 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Retinal Disease, Macular Degeneration
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD).
- Conditions
- Retinal Disease, Macular Degeneration, Age-Related Macular Degeneration, Geographic Atrophy
- Trial name
- NCT06394232
- Testing
- Eyecyte-RPE™
- Where
- 3 sites in India
- Volunteers
- 54 people
- Sponsor
- Eyestem Research Pvt. Ltd.
Age-Related Macular Degeneration, Macular Degeneration, Age-Related
Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients…
- Conditions
- Age-Related Macular Degeneration, Macular Degeneration, Age-Related, Dry Macular Degeneration, Geographic Atrophy
- Trial name
- METforMIN (NCT02684578)
- Testing
- Metformin
- Where
- 12 sites in United States
- Volunteers
- 66 people
- Sponsor
- University of California, San Francisco
Geographic Atrophy
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD).
- Trial name
- ArMaDa (NCT06018558)
- Testing
- OCU410
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ocugen
Non-Exudative (Dry) Age-related Macular Degeneration (dAMD)
Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD
This is a parallel, randomized, open-label, controlled study to evaluate the efficacy and safety of oral EG-301 in patients with intermediate non-exudative (dry) age-related macular degeneration (dAMD).
- Trial name
- NCT05170048
- Testing
- EG-301, AREDS2 supplements
- Volunteers
- 90 people
- Sponsor
- Evergreen Therapeutics, Inc.
Dry AMD, Stargardt Disease 1
Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease
Prospective, randomised, double-blind study to assess the Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (Macular Degeneration Omega-3 Study - MADEOS.
- Trial name
- MADEOS (NCT03297515)
- Testing
- Madeos
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 32 people
- Sponsor
- Ophthalmos Research and Education Institute